Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Quetiapine, Quetiapine XR
Quetiapine, formulation · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 003 | PLACEBO_COMPARATOR | Placebo Daily for 3 weeks |
| 002 | ACTIVE_COMPARATOR | Quetiapine 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks |
| 001 | EXPERIMENTAL | Paliperidone ER 3 to 12 mg daily, flexibly dosed, for 12 weeks |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Daily for 3 weeks |
| Quetiapine | DRUG | 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks |
| Paliperidone ER | DRUG | 3 to 12 mg daily, flexibly dosed, for 12 weeks |
Inclusion Criteria: * Meets Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM IV) criteria for Bipolar I Disorder, Most Recent Episode Manic or Mixed (with or without psychotic features) * history of at least 1 previously documented manic or mixed episode requiring medical t...
Top 9 of 10 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Xanomeline and trospium chloride, Xanomeline/Trospium Chloride |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Cariprazine, ABBV-932, Icalcaprant |
| Xenon Pharmaceuticals Inc. | XENE | 2 | PHASE3 | Azetukalner |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE2 | NBI-1117568 |
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-100 |
| LB Pharmaceuticals, Inc. | LBRX | 1 | PHASE2 | LB-102 |
| BioXcel Therapeutics, Inc. | BTAI | 1 | PHASE1 | BXCL501 |
| Alzamend Neuro, Inc. | ALZN | 1 | PHASE1 | AL001 |
Quetiapine is an oral small molecule therapy studied for bipolar disorder. It is being developed by Johnson & Johnson (ticker JNJ) and has been evaluated in a Phase 3 clinical trial in patients with bipolar I disorder and mood disorders. It is an investigational formulation in clinical development for this psychiatric indication.
Quetiapine targets HTR2A, DRD2, and HTR2C. It acts as an antagonist at these receptors, meaning it blocks their activity. HTR2A and HTR2C are serotonin receptors, while DRD2 is a dopamine receptor, and this combined receptor blockade underlies its therapeutic profile in psychiatry.
Johnson & Johnson, which trades under the ticker JNJ, is the developer of this quetiapine formulation. The company is advancing the oral small molecule in Phase 3 development for bipolar disorder within its psychiatry therapeutic area.
Quetiapine is in Phase 3 clinical development for bipolar disorder. It is an investigational oral formulation and is not described as approved. One Phase 3 trial has been completed, and no active trials are currently listed for this formulation.
Quetiapine has been studied in the Phase 3 trial NCT00309699, titled a study evaluating flexible doses of extended-release paliperidone compared with flexible doses of quetiapine and placebo in patients with bipolar I disorder. The completed trial enrolled 493 patients, was randomized, double-blind, and placebo-controlled, and ran across the United States, Greece, Lithuania, Russia, South Korea, Taiwan, Turkey, and Ukraine.
Quetiapine XR and quetiapine XR 50 mg are alternative names for this oral quetiapine formulation. Searches for quetiapine oral formulation, quetiapine, or quetiapine XR all refer to the same Johnson & Johnson small molecule being developed for bipolar disorder.